Achieve Life Sciences (NASDAQ: ACHV) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.
This table compares Achieve Life Sciences and Ionis Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Achieve Life Sciences||N/A||-126.78%||-101.46%|
This is a summary of current ratings and price targets for Achieve Life Sciences and Ionis Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Achieve Life Sciences||0||0||0||0||N/A|
Ionis Pharmaceuticals has a consensus target price of $50.92, indicating a potential upside of 1.39%. Given Ionis Pharmaceuticals’ higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Achieve Life Sciences.
Earnings & Valuation
This table compares Achieve Life Sciences and Ionis Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Achieve Life Sciences||$5.06 million||3.50||-$20.12 million||($5.30)||-0.28|
|Ionis Pharmaceuticals||$346.62 million||18.08||-$86.55 million||$0.15||334.82|
Achieve Life Sciences has higher earnings, but lower revenue than Ionis Pharmaceuticals. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Achieve Life Sciences has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 2.86, indicating that its share price is 186% more volatile than the S&P 500.
Institutional & Insider Ownership
3.3% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 91.4% of Ionis Pharmaceuticals shares are held by institutional investors. 35.8% of Achieve Life Sciences shares are held by insiders. Comparatively, 2.1% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Ionis Pharmaceuticals beats Achieve Life Sciences on 11 of the 13 factors compared between the two stocks.
About Achieve Life Sciences
Achieve Life Sciences, Inc., formerly OncoGenex Pharmaceuticals, Inc., is a clinical-stage pharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company’s product candidates include Custirsen, Cytisine and OGX-225. These products are designed to block the production of specific proteins that promotes treatment resistance and survival of tumor cells, and are over-produced in response to a variety of cancer treatments. The Company is focused on targeting these particular proteins to disable the tumor cell’s adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company’s subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.